Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Bohnen ShaneOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-2,259Price:--
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Bohnen ShaneOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-747Price:$67.87
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Bohnen ShaneOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:2,259Price:--
-
Mar 07, 2024 (filed on Mar 11, 2024)Insider Name:Nusse RoelandOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-10,400Price:$76.98
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Geist WilliamOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-1,111Price:$68.54
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:McManus MatthewOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:15,902Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:McManus MatthewOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:7,951Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:McManus MatthewOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:13,861Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:McManus MatthewOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,888Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Kelderman KimOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:51,890Price:--
Filings by filing date
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Bohnen ShaneOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-2,259Price:--
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Bohnen ShaneOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-747Price:$67.87
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Bohnen ShaneOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:2,259Price:--
-
Mar 07, 2024 (filed on Mar 11, 2024)Insider Name:Nusse RoelandOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-10,400Price:$76.98
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Geist WilliamOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-1,111Price:$68.54
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:McManus MatthewOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:15,902Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:McManus MatthewOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:7,951Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:McManus MatthewOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:13,861Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:McManus MatthewOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,888Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Kelderman KimOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:51,890Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 614 MCKINLEY PL N E MINNEAPOLIS MN 55413 |
Tel: | 1-612-6564416 |
Website: | https://www.bio-techne.com |
IR: | See website |
Key People | ||
Kim Kelderman Chief Executive Officer, Chief Operating Officer, Director | James T. Hippel Chief Financial Officer, Executive Vice President - Finance | William Alexander Geist President - Protein Sciences Segment |
Matthew F. Mcmanus President - Diagnostics and Genomics Segment | Shane Bohnen Senior Vice President, General Counsel, Company Secretary |
Business Overview |
Bio-Techne Corporation is a global life sciences company. The Company is engaged in providing tools and bioactive reagents for the research and clinical diagnostic communities. It operates through two segments: Protein Sciences and Diagnostics and Genomics. Its Protein Sciences segment develops and manufactures biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits. |
Financial Overview |
For the six months ended 31 December 2023, BIO-TECHNE Corp revenues increased 2% to $549.5M. Net income applicable to common stockholders decreased 44% to $78.4M. Revenues reflect Diagnostics and Genomics segment increase of 7% to $148.2M, U.K segment increase of 17% to $117.3M, United States segment increase of 1% to $306.9M, APAC, excluding Greater China segment increase of 3% to $36.4M. |
Employees: | 3,050 as of Jun 30, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $10,090M as of Dec 31, 2023 |
Annual revenue (TTM): | $1,145M as of Dec 31, 2023 |
EBITDA (TTM): | $389.24M as of Dec 31, 2023 |
Net annual income (TTM): | $224.12M as of Dec 31, 2023 |
Free cash flow (TTM): | $175.00M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $311.35M as of Dec 31, 2023 |
Shares outstanding: | 157,191,685 as of Feb 2, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |